Next Article in Journal
Antibiotic-Resistant Acinetobacter baumannii in Low-Income Countries (2000–2020): Twenty-One Years and Still below the Radar, Is It Not There or Can They Not Afford to Look for It?
Next Article in Special Issue
Perspectives of Healthcare Professionals Regarding Factors Associated with Antimicrobial Resistance (AMR) and Their Consequences: A Cross Sectional Study in Eastern Province of Saudi Arabia
Previous Article in Journal
Antibacterial Residue Excretion via Urine as an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment
Previous Article in Special Issue
Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 10
Issue 7
10.3390/antibiotics10070763
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study

by
Daniele Roberto Giacobbe
1,2,*,
Chiara Russo
1,2,
Veronica Martini
3,
Silvia Dettori
1,2,
Federica Briano
1,2,
Michele Mirabella
2,
Federica Portunato
2,
Chiara Dentone
2,
Sara Mora
4,
Mauro Giacomini
4,
Marco Berruti
1,2 and
Matteo Bassetti
1,2
1
Department of Health Sciences, University of Genoa, 16132 Genoa, Italy
2
Clinica Malattie Infettive, San Martino Policlinico Hospital—IRCCS, 16132 Genoa, Italy
3
School of Medicine, University of Genoa, 16132 Genoa, Italy
4
Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genoa, 16145 Genoa, Italy
*
Author to whom correspondence should be addressed.
Antibiotics 2021, 10(7), 763; https://doi.org/10.3390/antibiotics10070763
Submission received: 4 June 2021 / Revised: 15 June 2021 / Accepted: 21 June 2021 / Published: 23 June 2021
(This article belongs to the Special Issue Current and Novel Antimicrobial Strategies for Bacterial and Fungal Infections by Resistant Organisms)
Browse Figure
Versions Notes

Abstract

A single-center cross-sectional study was conducted to describe the use of ceftaroline in a large teaching hospital in Northern Italy, during a period also including the first months of the coronavirus disease 2019 (COVID-19) pandemic. The primary objective was to describe the use of ceftaroline in terms of indications and characteristics of patients. A secondary objective was to describe the rate of favorable clinical response in patients with bloodstream infections (BSI) due to methicillin-resistant Staphylococcus aureus (MRSA-BSI) receiving ceftaroline. Overall, 200 patients were included in the study. Most of them had COVID-19 (83%, 165/200) and were hospitalized in medical wards (78%, 155/200). Included patients with COVID-19 pneumonia were given empirical ceftaroline in the suspicion of bacterial co-infection or superinfection. Among patients with MRSA-BSI, ceftaroline was used as a first-line therapy and salvage therapy in 25% (3/12) and 75% (9/12) of cases, respectively, and as a monotherapy or in combination with daptomycin in 58% (7/12) and 42% (5/12) of patients, respectively. A favorable response was registered in 67% (8/12) of patients. Improving etiological diagnosis of bacterial infections is essential to optimize the use of ceftaroline in COVID-19 patients. The use of ceftaroline for MRSA-BSI, either as a monotherapy or in combination with other anti-MRSA agents, showed promising rates of favorable response.
Keywords: ceftaroline; MRSA; Staphylococcus aureus; COVID-19 ceftaroline; MRSA; Staphylococcus aureus; COVID-19

Share and Cite

MDPI and ACS Style

Giacobbe, D.R.; Russo, C.; Martini, V.; Dettori, S.; Briano, F.; Mirabella, M.; Portunato, F.; Dentone, C.; Mora, S.; Giacomini, M.; et al. Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study. Antibiotics 2021, 10, 763. https://doi.org/10.3390/antibiotics10070763

AMA Style

Giacobbe DR, Russo C, Martini V, Dettori S, Briano F, Mirabella M, Portunato F, Dentone C, Mora S, Giacomini M, et al. Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study. Antibiotics. 2021; 10(7):763. https://doi.org/10.3390/antibiotics10070763

Chicago/Turabian Style

Giacobbe, Daniele Roberto, Chiara Russo, Veronica Martini, Silvia Dettori, Federica Briano, Michele Mirabella, Federica Portunato, Chiara Dentone, Sara Mora, Mauro Giacomini, and et al. 2021. "Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study" Antibiotics 10, no. 7: 763. https://doi.org/10.3390/antibiotics10070763

APA Style

Giacobbe, D. R., Russo, C., Martini, V., Dettori, S., Briano, F., Mirabella, M., Portunato, F., Dentone, C., Mora, S., Giacomini, M., Berruti, M., & Bassetti, M. (2021). Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study. Antibiotics, 10(7), 763. https://doi.org/10.3390/antibiotics10070763

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop